There is much controversy about the pharmacokinetics and tumour uptake of radiolabelled antibodies. For example, tumour growth was accompanied by a linear uptake of 1251-labelled monoclonal antibody (MoAb) in a murine human tumour system while the antigen of that model was not detected in the circulation (Baldwin & Pimm, 1983) . Enlargement of tumours was accompanied by a measurable decrease in tumour concentration of "3'I-MoAb. This was a lymphoma model which produced a circulating antigen (Menard et al., 1983 ). An inverse relationship between tumour size and antibody uptake has been reported (Moshakis et al., 1981) . Nonspecific antibody uptake varied directly with the tumour size but was reduced by necrosis (Epenetos et al., 1982) . There may be some unidentified factors presumably related to biological differences in tumour vascularity and or necrosis. These factors may be responsible for the majority of the tumour-to-tumour variation (Christopher et al., 1985) .
Selective targeting of the tumours with radioactive antiferritin has been used in clinical cases as well as in experimental models (Order et al., 1986; Tang et al., 1990; Klein et al., 1989; Moroz et al., 1989) . Rostock et al. identified the features that allow hepatocellular cancer to be targeted selectively by '31I-antiferritin instead of the isotope being deposited in the ferritin-bearing organs (Rostock et al., 1983 (Rostock et al., , 1985 . We have investigated the therapeutic effect of radiolabelled antiferritin and have observed that the tumour concentration of ferritin is relatively higher in the early phase of tumour growth which helps to localise antibody, increases the absorbed dose of radiation, improves treatment and prolongs survival.
Materials and methods
Human tumour xenograft model Six to eight-week-old female athymic mice (nu/nu genotype, BALB/c background) weighing 22-30 g were used in all experiments. A ferritin-producing human hepatocellular carcinoma cell line (HC-04) was used; this was established and has been maintained in our department (Kuwahara, 1980 (Pressman, 1957 
Radiation dosimetry
Radiation doses to various tissues from infusion of 131-labelled antiferritin antibody and '3'I-labelled control IgG were calculated from the biodistribution of labelled antibody, assuming uniform distribution of isotope within individual organs. The area under the biodistribution curve was estimated from the mean percentage of ID g-' obtained for each antibody at 1, 6, 12 h and 1, 2, 3, 6 and 8 days using the trapezoidal integration method. Values for "3'I control antibody were calculated by correcting the data obtained for 1251 control antibody to the values that would have been obtained if the control antibody had been labelled with 13'I. The initial concentration of radiolabelled antibody in all tissues, except blood, was assumed to be 0% ID g-'. Initial concentrations of antibody in blood were assumed to be equivalent to the values at 1 h. Radiation doses were then calculated for a 1,000 jiCi initial antibody dose by multiplying the integrated jiCi h-' g -' by the g.cGy iCi ' h-1, which has been tabulated by the Medical Internal Radiation Dose Committee (Dillman, 1969) . For '3'I the value is 0.4165 for the total of all P-particles, low energy X-rays and Auger electrons, all of which are totally absorbed in the source organ where the isotope is deposited. The major fy-ray for '3'I is 0.364 MeV and deposits 0.6465 g.cGypjCi' hr-' but this energy is poorly absorbed with only 10% deposited in a sphere with a radius of 3 cm. Thus for the small organs in a mouse, the y component to the absorbed dose has been neglected. We elected to calculate cumulative radiation doses by estimating the integral of the mean biodistribution curves rather than by the effective half-life method for the reason that, in several tissues, particularly tumour, uptake of labelled antibody occurred over a 24-48 h period. Using the trapezoidal method of integration results in a slightly higher calculated radiation dose for portions of the clearance curves that are concave and slightly lower doses for curves that are convex compared to the effective half-life method. The differences in calculated dose between the two methods are small compared to the differences between animals that would result from the variation in antibody concentrations in tissues (Christopher et al., 1985) .
Results

Concentration offerritin in tumour and blood
The level of ferritin in the blood and tissues of normal mice was measured by IRMA. The serum level of ferritin was 0-30 ng ml-'; ferritin could not be detected in tissue from the heart, lung, liver, spleen and kidney. Fifteen days after inoculation of tumour, the mean blood level of ferritin was 10 ng ml' while the mean tumour concentration was 2,100ngmg-' protein. Thirty days after inoculation, the mean level of ferritin in the blood was 70 ng ml-' and the mean tumour concentration was 3,500 ng mg' protein. The concentration of tumour ferritin tends to decline on day 40 after inoculation and that of blood ferritin on day 50 after inoculation.
Antibody localization
The biodistribution of radiolabelled antibody was measured after a single infusion. The localisation of '3'I-labelled antiferritin antibody and '25M-labelled control antibody to tumour and normal organs is shown in Figure 1 . Clearance of both 13'I poly and 1251 control antibody from blood, lung, liver and kidney demonstrated almost exponential decline over time and clearance rates were similar among these tissues for both 13'I poly and 1251I control antibody.
Influence of antibody dose on biodistribution The influence of antibody dose on biodistribution was determined by infusing a single bolus over a 250-fold range from 10-2,500 fig per animal and the concentration of 1311-poly in tissues was determined 24 h after infusion (Figure 2 ). There was no significant change (P = 0.43) in concentration of '31I-polyclonal antiferritin in tumour as the dose varied from 10-400 jg per animal. There was a significant decrease (P = 0.05) in concentration of radioactive antibody in tumour as the dose was increased from 400-2,500lig per animal. In contrast, there was no evidence (P = 0.17) of antibody dose influencing the concentration of radiolabelled control antibody present in tumour over the range of 10-2,500 jg per animal. However, the comparative study between early and late administration indicated a relatively significant increase in antibody concentration in tumour in the case of "311-labelled antiferritin (P <0.05) but not 131I-labelled control antibody. There were no differences among doses in the proportion of antibody localising to normal organs for either polyclonal antiferritin, or control antibody (details not shown). The biodistribution over time of total doses of antibody varying from 10-1,000jig per animal was similar to that shown in Figure 1 . Thus, radiolabelled antiferritin, at a dose of up to 400 ig per animal, could be administered for maximum localisation to tumour.
Toxicity and dosimetry
To determine the maximum nonlethal dose of "'lI antiferritin polyclonal antibody, the mice received infusions of 500-2,000 jiCi of 131I-labelled polyclonal antiferritin. All mice survived following infusion of 500 or 1,000 iCi of 1311-labelled polyclonal antiferritin. Approximately 50% of animals died within 15-20 days after infusion of 1,500 iCi with the remainder surviving more than 50 days. All of the animals died within 2 weeks after infusion of 2,000jiCi.
Histological examination of animals receiving 1,000 jCi of '3'I-labelled antibody showed severe hypoplasia of the bone marrow (approximately 15-20% normal cellularity) 2 weeks after infusion, with recovery of marrow cellularity by day 25. Administration of 500 iCi did not produce any sign of toxicity and, therefore, was the dose of choice in this experimental study.
An approximation of the relative radiation doses that would be delivered to tumour and critical normal tissues by infusion of 1,000 Ci of '31I-labelled polyclonal antiferritin was calculated from the biodistribution curves shown in Figure 1 , assuming uniform distribution of isotope in the tumour and 100% absorption of all emitted P particles (Table I) The survival curves of mice treated with 500 ICi '3'Ilabelled polyclonal antiferritin in group A and group B were compared to those of a control group. Injections of 500 fiCi of "3'I-labelled polyclonal antiferritin in group B increased median survival by 25% over control animals that had received saline (P = 0.06). Administration of 500 iLCi of ''Ilabelled polyclonal antiferritin in group A produced enhancement of survival of greater statistical significance (P = 0.009) (Figure 3) .
Discussion
A high level of serum ferritin has been associated with various neoplastic conditions, including hepatocellular carcinoma (Cohen et al., 1984 (Cohen et al., , 1985 Kew et al., 1978; Nittsu et al., 1975 (Lundstedt et al., 1985) . ed median survival of 25% in Group B over control There have been reports that requirements for therapy with that had received saline (P = 0.06). Enhancement of radiolabelled antibodies are different from those for imaging I of greater statistical significance (P = 0.009) over control (Larson et al., 1983; Leichner et al., 1983; Rostock et al., coxon-Gehan test. 1983) . Our findings suggest a common requirement for treatment and for imaging, that is, increased concentration of tumour ferritin in the early phase of tumour growth. al., 1986; Zhang et al., 1988) . Specificity of antibody Therefore, we conclude that it is possible to equate the Msified isotopic radiation may increase the tumour antigen expression as a function of tumour growth time with position and tumour cytotoxicity (Klein et al., 1989) .
localisation of antibody and thus with radiation dosimetry r, before, and after, treatment, the relationship from '31I-labelled antiferritin antibody and therapeutic rethe level of blood and tumour ferritin and its effect sponses. on the therapeutic response has not been clarified. Moreover, the significance of the time of onset of therapy in terms of the above factors has not been adequately explained.
We investigated the level of ferritin in blood and in tumour at various intervals after inoculation of tumour cells. The therapeutic response of antiferritin polyclonal antibody appeared to be related primarily to the relative concentration of ferritin in the tumour tissue. During the first few weeks after inoculation, the concentration of tumour ferritin rose progressively although the blood level remained normal. The onset of treatment at this phase was more effective. On the other hand, a relatively higher level of blood ferritin made 
